What Is MOTS-C?

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide first identified in 2015 by researchers at the University of Southern California, encoded within the mitochondrial genome’s 12S rRNA region rather than nuclear DNA. It belongs to a small class of mitochondrial-derived peptides (MDPs) that includes humanin and the SHLP (small humanin-like peptide) family. Research has focused primarily on its role in activating AMPK (AMP-activated protein kinase), a central regulator of cellular energy metabolism, and its apparent ability to translocate to the nucleus under metabolic stress to influence gene expression.

Reconstitution: How It’s Done in Research Settings

MOTS-C is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted with a sterile diluent before use in a research protocol. Bacteriostatic water is the most commonly reported diluent in published and community research documentation, chosen for its 0.9% benzyl alcohol content, which helps inhibit bacterial growth across multiple draws from the same vial.

The general reconstitution approach reported across research literature follows this math:

• Concentration formula: milligrams of peptide ÷ milliliters of diluent added = concentration in mg/mL.
• Example: a 10mg vial reconstituted with 2mL of bacteriostatic water yields a 5mg/mL solution.
• Syringe conversion: most insulin syringes are marked in units (1mL = 100 units), so a 5mg/mL solution delivers 0.5mg per 10 units drawn.

Diluent should be added slowly, directed against the side of the vial rather than straight onto the lyophilized powder, to avoid degrading the peptide structure through excess agitation or foaming.

Storage Conditions Reported in the Literature

Peptide stability research consistently reports two storage states:

• Lyophilized (unreconstituted) powder: stored frozen (-20°C or colder) and protected from light, where it is generally reported to remain stable for extended periods, often cited as 1-2 years, though manufacturer-specific testing varies.
• Reconstituted solution: stored refrigerated (2-8°C), with most research and manufacturer documentation reporting usable stability for approximately 20-30 days before noticeable degradation.

Repeated freeze-thaw cycles, exposure to direct light, and storage at room temperature are the three variables most consistently associated with accelerated peptide degradation across stability studies of short-chain research peptides generally.

Dosing Ranges Reported in Published Research

Dosing in published MOTS-C research varies substantially by study design, delivery route, and research model (in-vitro, rodent, or early human trials). Reported figures include:

• Early-phase human clinical research (registered trials studying metabolic parameters) has used subcutaneous dosing in the low-milligram range on a scheduled basis, with exact protocols varying by trial design and research phase.
• Rodent studies, which make up the majority of published MOTS-C literature to date, use weight-adjusted dosing (typically reported in mg/kg) that does not translate directly to a human-equivalent dose without proper allometric scaling, something only qualified researchers should calculate.
• Community-reported research protocols commonly reference dosing in the 5-10mg per week range, split across multiple smaller doses, though this figure comes from informal research-community documentation rather than a single peer-reviewed source, and should be treated accordingly.

Because dosing data is this fragmented across study types, anyone conducting legitimate research with MOTS-C should reference the specific published protocol most relevant to their research design, rather than treating any single number on this page as a standard.

Cycle Length in Research Protocols

Published studies on MOTS-C and related mitochondrial-derived peptides have used research windows ranging from several weeks to multiple months, often tied to the specific metabolic marker being studied (such as insulin sensitivity or exercise capacity measures). There is no single agreed-upon “cycle length” in the literature; protocol duration is a study-design decision, not a fixed rule.

Administration Routes Reported in Studies

Subcutaneous injection is the most commonly reported administration route in both clinical and community research documentation for MOTS-C, consistent with how most short-chain research peptides are handled in laboratory settings. Oral bioavailability for peptides of this class is generally very low due to rapid digestive breakdown, which is why injectable routes dominate the published research.

Related Questions

For questions on side effects, legality, and how MOTS-C compares to other metabolic-research peptides, see the full MOTS-C FAQ.